Galectin‑3 in patients with left ventricular hypertrophy and metabolic syndrome
https://doi.org/10.18705/1607-419X-2018-24-3-272-280
Abstract
Objective. To investigate the serum levels of galectin‑3 in patients with metabolic syndrome (MS) and in patients with combination of MS and left ventricular hypertrophy (LVH), as well as to define the role of this marker of fibrosis in MS.
Design and methods. The study included 43 patients with MS (33 patients had LVH), and 33 patients of comparable age without MS (LVH was diagnosed in 10). The level of serum galectin‑3 was determined by enzyme immunoassay kits Platinum ELISA.
Results. The average level of galectin‑3 in the MS group was significantly higher (1,89 ± 1,71 ng/ml), compared to the group without MS (1,03 ± 0,22 ng/ml, p = 0,006). The study showed a positive correlation between the level of galectin‑3 and LVH (r = 0,323, p = 0,004). The mean value of galectin‑3 in patients with no evidence of LVH was 1,2 ± 0,76 ng/ml, in patients with LVH — 2,1 ± 2,02 ng/ml.
Conclusions. In patients with MS the level of galectin‑3 was higher than in patients without MS, and in patients with MS and concomitant LVH it was higher than in patients without LVH. In patients with MS and LVH increased galectin‑3 levels may indicate the severity of myocardial fibrosis and help for prognosis evaluation.
About the Authors
O. M. Drapkina
National Medical Research Center for Preventive Medicine
MD, PhD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Director,
R. N. Shepel
National Medical Research Center for Preventive Medicine
Russian Federation
Russian Federation
MD, Assistant Director on Regional Development Programs, Head, Department of Organizational and Methodological Management and Health Care Expertise, Researcher, Department of Functional and Practical Issues of Obesity,
T. A. Deeva
I. M. Sechenov First Moscow State Medical University
MD, PhD Student, Department of Propaedeutics, Medical Faculty
MD, PhD Student, Department of Propaedeutics, Medical Faculty
A. N. Kaburova
National Medical Research Center for Preventive Medicine
MD, Researcher, Department of Functional and Practical Issues of Obesity,
References
1. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35(2):580–586.
2. Драпкина О.М., Елиашевич С.О., Шепель Р.Н. Ожирение как фактор риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2016;6:73–79. [Drapkina OM, Eliashevich SO, Shepel RN. Obesity is a risk factor for chronic noncommunicable diseases. Russian Journal of Cardiology. 2016;6:73–79. In Russian].
3. Levy D, Murabito JM, Anderson KM, Christiansen JC, Castelli WP. Echocardiographic left ventricular hypertrophy — clinical characteristics — the Framinghan Heart Study. Clin Exp Hypertens. 1992;14(1–2):58–97.
4. Lind L, Andersson P, Andren L, Hänni A, Lithell HO. Left ventricular hypertrophy is associated with the insulin resistance metabolic syndrome. Hypertension. 1995;13(4):433–438.
5. Vasan RS. Cardiac function and obesity. Heart. 2003;89 (10):1127–1129.
6. Драпкина О. М., Дуболазова Ю. В. Характеристики пульсовой волны у пациентов c артериальной гипертензией и сердечной недостаточностью с сохраненной фракцией выброса. Российские медицинские вести. 2012;17(4):20–31. [Drapkina OM, Dubolazova YuV. Characteristics of pulse wave in patients with systemic hypertension and heart failure with preserved ejection fraction. Russian Medical News. 2012;17(4):20–31. In Russian].
7. Dumic J, Dabelic S, Flogel M. Galectin 3: an open-ended story. Biochim Biophys Acta. 2006;1760(4):616–635.
8. Alberti KG, Zimmet PZ, Shaw JE. The metabolic syndrome — a new worldwide definition from the International diabetes federation consensus. Diabet Med. 2006;23(5):469–480.
9. Ferrara LA, Cardoni O, Mancini M, Zanchetti A. Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the Gubbio Study. J Hum Hypertens. 2007;21 (10):795–801.
10. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN et al. Serum galectin 3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab. 2010;95(3):1404–1411.
11. Ионин В.А., Листопад О.В., Нифонтов С.Е., Васильева Е.Ю., Соболева А.В., Беляева О.Д. и др. Галектин 3 у пациентов с метаболическим синдромом и фибрилляцией предсердий. Артериальная гипертензия. 2014;20(5):49–83. [Ionin VA, Listopad OV, Nifontov SE, Vasiljeva EYu, Soboleva AV, Belyaeva OD et al. Galectin 3 in patients with metabolic syndrome and atrial fibrillation. Arterial’naya Gipertenziya = Arterial Hypertension. 2014;20(5):49–83. In Russian].
12. Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A. Increased levels of galectin–3 were associated with prediabetes and diabetes: new risk factor? J Endocrinol Invest. 2014;38(5):1–7.
13. Драпкина О. М., Шепель Р. Н., Деева Т. А. Оценка уровня галектина 3 у пациентов с метаболическим синдромом и ишемической болезнью сердца. Российский кардиологический журнал. 2017;3:30–36. [Drapkina OM, Shepel RN, Deeva TA. Galectin 3 level in patients with metabolic syndrome and coronary heart disease. Russian Journal of Cardiology. 2017;3: 30–36. In Russian].
14. Базаева Е.В., Мясников Р.П., Метельская В.А., Бойцов С.А. Диагностическая значимость биохимических маркеров при хронической сердечной недостаточности со сниженной, пограничной и сохраненной фракцией выброса левого желудочка. Кардиология. 2017;57(3):58–64. [Bazaeva EV, Myasnikov RP, Metelskaya VA, Boytsov SA. Diagnostic value of biochemical markers in patients with chronic heart failure with reduced, borderline and preserved left ventricular ejection fraction. Kardiologiia. 2017;57(3):58–64. In Russian].
15. de Boer RA, Lok D, Hillege JL, Voors AA, Gilst WH, Jaarsma T et al. Clinical and prognostic value of galectin 3, a novel fibrosis-associated biomarker. Relation with clinical and biochemical correlates of heart failure. J Am Coll Cardiol. 2010; 55: A2.
16. Nayor M, Wang N, Larson MG, Vasan RS, Levy D, Ho JE. Circulating Galectin 3 is associated with cardiometabolic disease in the community. J Am Coll Cardiol. 2015;5(1):1–7.
17. Nar G, Aksan G, Gorgulu O, Inci S, Soylu K, Ozdemir M et al. Galectin 3 as a novel biomarker for the diagnosis of essential hypertension with left ventricular hypertrophy. J Exp Clin Med. 2016;33(3):123–128.
Review
For citations:
Drapkina O.M., Shepel R.N., Deeva T.A., Kaburova A.N. Galectin‑3 in patients with left ventricular hypertrophy and metabolic syndrome. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2018;24(3):272-280. (In Russ.) https://doi.org/10.18705/1607-419X-2018-24-3-272-280
Views:
1277
Email this article 